H3F3A K27M mutations in thalamic gliomas from young adult patients

Neuro-Oncology

Volumn 16, Issue 1, 2014, Pages 140-146

  Aihara, Koki ^a,b   Mukasa, Akitake ^a   Gotoh, Kengo ^b   Saito, Kuniaki ^a   Nagae, Genta ^b   Tsuji, Shingo ^b   Tatsuno, Kenji ^b   Yamamoto, Shogo ^b   Takayanagi, Shunsaku ^a   Narita, Yoshitaka ^c   Shibui, Soichiro ^c   Aburatani, Hiroyuki ^b   Saito, Nobuhito ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

H3F3A mutation.; thalamic glioma; young adult

Indexed keywords

DNA; HISTONE H3; HISTONE H3F3A; UNCLASSIFIED DRUG; HISTONE; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CHROMATIN; CLINICAL ARTICLE; DNA METHYLATION; GENE MUTATION; GLIOMA; HUMAN; MIDDLE AGED; MODIFIER GENE; THALAMIC GLIOMA; TUMOR GENE; YOUNG ADULT; AGED; BRAIN DISEASE; BRAIN TUMOR; CANCER GRADING; FEMALE; FOLLOW UP; GENETICS; MALE; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HISTONES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROGNOSIS; SURVIVAL RATE; THALAMIC DISEASES; YOUNG ADULT;

EID: 84891546869     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not144     Document Type: Article

References (26)

1. Cheek WR, Taveras JM. Thalamic tumors. J Neurosurg. 1966;24(2): 505-513
2. Mckissock W, PaineKW. Primary tumours of the thalamus. Brain. 1958; 81(1):41-63
3. Tovi D, Schisano G, Liljeqvist B. Primary tumors of the region of the thalamus. J Neurosurg. 1961;18:730-740
4. Kelly PJ. Stereotactic biopsy and resection of thalamic astrocytomas. Neurosurgery. 1989;25(2):185-194
5. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226-231
6. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251-253
7. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425-437
8. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al.K27Mmutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012; 124(3):439-447
9. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760
10. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303
11. Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164
12. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26
13. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59(1):67-70
14. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068
15. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 2013; 125(5):659-669
16. Mukasa A, Takayanagi S, Saito K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012;103(3):587-592
17. Fontebasso AM, Liu XY, Sturm D, Jabado N. Chromatin remodeling defects in pediatric and young adult glioblastoma: A tale of a variant histone 3 tail. Brain Pathol. 2013;23(2):210-216
18. Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A, Pietsch T. H3F3A K27M mutation in pediatric CNS tumors: A marker for diffuse high-grade astrocytomas. Am J Clin Pathol. 2013;139(3):345-349
19. Goldberg AD, Banaszynski LA, Noh KM, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell. 2010;140(5):678-691
20. Vastenhouw NL, Schier AF. Bivalent histone modifications in early embryogenesis. Curr Opin Cell Biol. 2012;24(3):374-386
21. Venneti S, Garimella MT, Sullivan LM, et al. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 2013;23(5): 558-564
22. Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-functionH3mutation found in pediatric glioblastoma. Science. 2013;340(6134):857-861
23. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet. 2011;12(1):7-18
24. Shibui S. Report of Brian Tumor Registry of Japan (1984-2000). Neurol Med Chir (Tokyo). 2009;49:1-101
25. Sanai N, Polley MY, Mcdermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3-8
26. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10): 997-1003